share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Bruno Julianne

CRISPR Therapeutics | 4:持股变动声明-高管 Bruno Julianne
美股SEC公告 ·  06/24 17:36
Moomoo AI 已提取核心信息
CRISPR Therapeutics COO Julianne Bruno sold 3,366 shares of the company's common stock on 06/21/2024, as per the latest SEC filings. The shares were sold at a price of $56.09 each, totaling approximately $188,798.94. This transaction followed an acquisition of 7,000 shares on 06/20/2024 through the exercise of derivative securities. After these transactions, Bruno directly holds 6,745 shares of CRISPR Therapeutics. Additionally, Bruno has an indirect beneficial ownership of 7,088 shares through The Julianne Bruno 2022 GRAT. The transactions have been reported as completed.
CRISPR Therapeutics COO Julianne Bruno sold 3,366 shares of the company's common stock on 06/21/2024, as per the latest SEC filings. The shares were sold at a price of $56.09 each, totaling approximately $188,798.94. This transaction followed an acquisition of 7,000 shares on 06/20/2024 through the exercise of derivative securities. After these transactions, Bruno directly holds 6,745 shares of CRISPR Therapeutics. Additionally, Bruno has an indirect beneficial ownership of 7,088 shares through The Julianne Bruno 2022 GRAT. The transactions have been reported as completed.
CRISPR Therapeutics首席运营官Julianne Bruno于06/21/2024根据最新的SEC文件出售了公司普通股的3,366股。每股售价为56.09美元,总价值约为188,798.94美元。此次交易是在通过衍生证券行使权利收购了7,000股股份后进行的。在这些交易之后,Bruno直接持有CRISPR Therapeutics的6,745股股份。此外,Bruno通过The Julianne Bruno 2022 GRAT拥有7,088股间接受益所有权。这些交易已被报告为已完成。
CRISPR Therapeutics首席运营官Julianne Bruno于06/21/2024根据最新的SEC文件出售了公司普通股的3,366股。每股售价为56.09美元,总价值约为188,798.94美元。此次交易是在通过衍生证券行使权利收购了7,000股股份后进行的。在这些交易之后,Bruno直接持有CRISPR Therapeutics的6,745股股份。此外,Bruno通过The Julianne Bruno 2022 GRAT拥有7,088股间接受益所有权。这些交易已被报告为已完成。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息